Abstract
The functional neuropeptide S receptor 1 (NPSR1) gene A/T variant (rs324981) is associated with fear processing. We investigated the impact of NPSR1 genotype on fear processing and on symptom reduction following treatment in individuals with spider phobia. A replication approach was applied [discovery sample: Münster (MS) nMS = 104; replication sample Würzburg (WZ) nWZ = 81]. Participants were genotyped for NPSR1 rs324981 [T-allele carriers (risk) versus AA homozygotes (no-risk)]. A sustained and phasic fear paradigm was applied during functional magnetic resonance imaging. A one-session virtual reality exposure treatment was conducted. Change of symptom severity from pre to post treatment and within session fear reduction were assessed. T-allele carriers in the discovery sample displayed lower anterior cingulate cortex (ACC) activation compared to AA homozygotes independent of condition. For sustained fear, this effect was replicated within a small cluster and medium effect size. No association with symptom reduction was found. Within-session fear reduction was negatively associated with ACC activation in T-allele carriers in the discovery sample. NPSR1 rs324981 genotype might be associated with fear processing in the ACC in spider phobia. Interpretation as potential risk-increasing function of the NPSR1 rs324981 T-allele via impaired top-down control of limbic structures remains speculative. Potential association with symptom reduction warrants further research.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Brede, Leonie S 1 ; Böhnlein, Joscha 1 ; Roesmann, Kati 2 ; Gathmann, Bettina 3 ; Herrmann, Martin J 4 ; Junghöfer, Markus 5 ; Schwarzmeier, Hanna 4 ; Seeger, Fabian R 4 ; Siminski, Niklas 4 ; Straube, Thomas 3 ; Klahn, Anna Luisa 6 ; Weber, Heike 4 ; Schiele, Miriam A 7 ; Domschke, Katharina 7 ; Lueken, Ulrike 4 ; Dannlowski, Udo 1 1 Institute for Translational Psychiatry, University of Münster , Münster 48149, Germany
2 Institute for Clinical Psychology, University of Siegen , Siegen 57072, Germany
3 Institute of Medical Psychology and Systems Neuroscience, University of Münster , Münster 48149, Germany
4 Department of Psychiatry, Psychosomatics, and Psychotherapy, Center of Mental Health, University Hospital of Würzburg , Wurzburg 97080, Germany
5 Institute for Biomagnetism and Biosignalanalysis, University of Münster , Münster 48149, Germany
6 Department of Psychiatry and Neurochemistry, University of Gothenburg , Gothenburg 41345, Sweden
7 Department of Psychiatry and Psychotherapy, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg , Freiburg 79104, Germany





